Altered Mental Status and Hyponatremia After 20 Hours of Amiodarone Therapy

A 66-year-old woman with no relevant medical history presented at the emergency department with new-onset atrial fibrillation. We initiated intravenous amiodarone therapy. At 20 hours, the patient experienced severe neurologic symptoms, hyponatremia, and syndrome of inappropriate antidiuretic hormone. We discontinued amiodarone, infused saline solution, and restricted the patient's fluid intake. She recovered in 3 days. This case illustrates that amiodarone-induced syndrome of inappropriate antidiuretic hormone with hyponatremia can occur far earlier than expected during acute amiodarone therapy.

Amiodarone is prescribed to treat various cardiac dysrhythmias. Unlike long-term amiodarone therapy, which is associated with many adverse effects, short-term amiodarone therapy is typically tolerated well, except for occasional pulmonary, hepatic, or cardiac toxicity.1 We report the case of a patient who was given amiodarone intravenously; within 24 hours, she developed syndrome of inappropriate antidiuretic hormone (SIADH), as evidenced by severe hyponatremia, high urinary osmolality, and disorientation.

Case Report

In March 2017, a 66-year-old woman with no relevant medical history, addictions, or medication use sought emergency medical attention for palpitations. She had atrial fibrillation with a rapid ventricular response at 112 beats/min and a blood pressure of 144/98 mmHg. Physical examination revealed no evidence of thyroid, pulmonary, or cardiac disease. Results of a complete blood count test and metabolic, hepatic, and thyroid panels were within normal ranges. She was admitted to the hospital.

We initiated intravenous heparin and diltiazem therapy, administered a 150-mg bolus of amiodarone, and then infused amiodarone at 1 mg/min for 6 hours. Finally, the amiodarone infusion was reduced to 0.5 mg/min for 18 hours. At 20 hours, the patient became somnolent, confused, and incoherent. Chest radiographs showed nothing of note; a neurologic examination revealed no motor deficit; and a computed tomogram of the head showed no anomaly. The patient’s serum sodium level had decreased from 140 mEq/L on admission to 112 mEq/L, and her urine osmolality was 484 mOsm/kg. In the absence of overt malignancy, pulmonary infection, and existing central nervous system disorders, we attributed the patient’s hyponatremia and neurologic symptoms to drug-induced SIADH. We discontinued the amiodarone and diltiazem, started beta-adrenergic blockade with metoprolol tartrate for control of ventricular response to atrial fibrillation, and administered a 100-mL bolus of 3% hypertonic saline solution. The saline solution was then infused at 30 mL/hr for 24 hours, with the goal of increasing her sodium level by 10 mEq/L over 24 hours.

At 72 hours, the patient’s serum sodium level was 133 mEq/L, her urine sodium level was <5 mmol/L, her urine osmolality was 55 mOsm/kg, and she had recovered normal mental status (Table I). Her morning plasma cortisol level was within normal range. At 120 hours, when the electrolyte imbalance was resolved, she began undergoing direct-current cardioversion. She was discharged from the hospital after a 10-day stay, with instructions to take metoprolol. She was lost to follow-up thereafter.
Amiodarone maintenance therapy is associated with adverse effects, including corneal microdeposits (in >90% of patients), photosensitivity (25%–75%), hepatotoxicity (15%–30%), pulmonary fibrosis (1%–7%), hypothyroidism (6%), bradycardia (≤10%), ataxia (3%–35%), and peripheral neuropathy (0.3%). Adverse effects occur far less frequently during intravenous therapy or oral loading; respiratory and hepatic failure have been reported. It is possible, but not established, that amiodarone therapy induces or worsens chronic heart failure and ventricular arrhythmias.

Many reports of amiodarone’s acute adverse effects in fact refer to short exposures of a few days to 6 months. Table II summarizes this issue in terms of amiodarone-induced hyponatremia and SIADH. Of 15 previous patients in whom amiodarone-induced SIADH developed, only 6 were given amiodarone for less than 2 weeks and none for less than 3 days. In contrast, our patient had a hyperacute response. Except for age, she had no conditions associated with increased antidiuretic hormone (ADH) release, such as small-cell carcinoma of the pancreas, hypothyroidism, adrenal insufficiency, or lung abscess from tuberculosis pneumonia. What caused our patient’s hyperacute response is unclear. Her kidneys may have been particularly sensitive to ADH, amiodarone may have increased ADH release, or both. Amiodarone was the most likely cause of SIADH in our patient; however, her severe symptoms and the risk of seizures precluded a repeat amiodarone challenge.

**Conclusion**

Our patient’s severe neurologic symptoms and laboratory findings of SIADH developed within 24 hours of intravenous amiodarone therapy. Amiodarone-induced SIADH with hyponatremia is a rare complication, and our report illustrates that it can occur far earlier than typically seen during acute amiodarone therapy. Recognizing SIADH and immediately discontinuing amiodarone therapy—along with saline infusion and fluid management—successfully reversed our patient’s symptoms.

*Patient was diagnosed with hyponatremia.*

**Discussion**

TABLE I. Patient’s Course

| Variable                        | Time (hr)   |
|---------------------------------|-------------|
|                                 | Admission   | 20*   | 46   | 72   |
| Sodium (mEq/L)                  | 140         | 112   | 127  | 133  |
| Heart rate (beats/min)          | 112         | 129   | 71   | 88   |
| Blood pressure (mmHg)           | 144/98      | 133/105| 107/58| 134/86|
| Urine osmolality (mOsm/kg)      | —           | 484   | —    | 55   |
| Mental status                   | —           | Disoriented | —    | Normal|
| Treatment                       | Amiodarone started | Amiodarone stopped within 1 hr | —    | —    |
|                                 | Metoprolol and 3% hypertonic saline solution started | Fluids restricted to 1,200 mL/d | —    | —    |
TABLE II. Reported Cases of SIADH and Hyponatremia Induced by Amiodarone

| Reference                  | Age (yr), Sex | Amiodarone Dose | Time to Hyponatremia | Lowest Serum Sodium Level (mEq/L) | Treatment | Time to Normal Serum Sodium (d) |
|----------------------------|---------------|------------------|----------------------|----------------------------------|-----------|-------------------------------|
| Muñoz Ruiz AI, et al. 8 (1996) | 67, F         | NA               | 4 mo                 | 110                              | Discontinued | NA                           |
| Odeh M, et al. 9 (1999)     | 62, F         | 300 mg/d         | 6 mo                 | 120                              | Discontinued | 5                            |
| Ikegami H, et al. 30 (2002) | 63, M         | 800 mg/d         | 7 d                  | 119                              | Decreased to 100 mg/d; fluid restriction | 28               |
|                            | 87, M         | 200 mg/d × 7 d; 100 mg/d | 15 d              | 121                              | Continued at 100 mg/d; fluid restriction | 14               |
| Patel GP and Kasiar JB 11 (2002) | 67, M         | 200 mg/d         | 3 mo                 | 117                              | Discontinued; fluid restriction | 3                |
| Aslam MK, et al. 12 (2004)  | 72, M         | 2 g/d loading    | 5 d                  | 117                              | Decreased to 200 mg/d | 14               |
| Yoshikawa S, et al. 18 (2006) | 87, M         | NA               | 10 d                 | 114                              | Fluid restriction | NA                           |
| Shavit E and Sherer Y 14 (2007) | 85, M         | NA               | 30 d                 | 122                              | Discontinued | A few days                    |
| Paydas S, et al. 15 (2008)  | 58, M         | NA               | 5 mo                 | 107                              | Discontinued | 14                           |
| Afshinnia F, et al. 16 (2011) | 66, M         | 150-mg IV; 900-mg drip for 24 hr; 400 mg 3×/d | 7 d                  | 116                              | Discontinued | 16                           |
| Singla S, et al. 17 (2013)  | 58, M         | 1,600 mg/d       | 3 d                  | 120                              | Discontinued; dialysis | NA                           |
| Pham L, et al. 18 (2013)    | 84, M         | 150-mg IV bolus and drip; 1,200 mg × 7 d; 400 mg/d | 11 d              | 105                              | Hypertonic saline solution; fluid restriction; oral demeclocycline | 10               |
| Dutta P, et al. 19 (2014)   | 63, M         | 100 mg/d         | 9 mo                 | 109                              | Discontinued; fluid restriction | 3                |
| Maloberti A, et al. 20 (2015) | 78, M         | 200 mg/d         | 5 yr                 | 110                              | Discontinued; hypertonic saline solution; fluid restriction | 1                |
| Nakamura M, et al. 21 (2017) | 43, M         | 200 mg/d         | 8 mo                 | 108                              | Discontinued; fludrocortisone | 30               |
| Current case                | 66, F         | 150-mg bolus; 1 mg/min for 6 hr; 0.5 mg for 18 hr | 20 hr              | 112                              | Discontinued; 100-mL bolus + 30-mL/hr infusion of 3% hypertonic saline solution; fluid restriction | 3                |

IV = intravenous; NA = not available; SIADH = syndrome of inappropriate antidiuretic hormone
References

1. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991;121(1 Pt 1):158-71.

2. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):1312-22.

3. Baumann H, Fichtenkamm P, Schneider T, Biscoping J, Henrich M. Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection - a case report and review of recent literature. Ann Med Surg (Lond) 2017;21:53-7.

4. Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf 2013;5:191-8.

5. Jaiswal P, Attar BM, Yap JE, Devani K, Jaiswal R, Wang Y, et al. Acute liver failure with amiodarone infusion: a case report and systematic review. J Clin Pharm Ther 2018;43(1):129-33.

6. Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein MC, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [published erratum appears in Circulation 2016;134(12):e261]. Circulation 2016;134(6):e32-e69.

7. Singh VK, Maheshwari V. Acute respiratory distress syndrome complicated by amiodarone induced pulmonary fibrosis: don’t let your guard down. J Clin Diagn Res 2017;11(4):UD01-02.

8. Munoz Ruiz AI, Calvo Elipe A, Guerrero Vega E, Gorgojo Martinez JJ, Vera Lopez E, Gilsanz Fernandez C. Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone [in Spanish]. An Med Interna 1996;13(3):125-6.

9. Odeh M, Schiff E, Oliven A. Hyponatremia during therapy with amiodarone. Arch Intern Med 1999;159(21):2599-600.

10. Ikegami H, Shiga T, Tsushima T, Nirei T, Kasanuki H. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by amiodarone: a report on two cases. J Cardiovasc Pharmacol Ther 2002;7(1):25-8.

11. Patel GP, Kasiar JB. Syndrome of inappropriate antidiuretic hormone-induced hyponatremia associated with amiodarone. Pharmacotherapy 2002;22(5):649-51.

12. Asham MK, Gnaim C, Kutnick J, Kowal RC, McGuire DK. Syndrome of inappropriate antidiuretic hormone secretion induced by amiodarone therapy. Pacing Clin Electrophysiol 2004;27(6 Pt 1):831-2.

13. Yoshikawa S, Suzuki M, Ichihara N, Sato S, Arakawa T, Matsumura A, et al. Interstitial pneumonitis followed by syndrome of inappropriate antidiuretic hormone secretion induced by amiodarone therapy for dilated cardiomyopathy: a case report [in Japanese]. J Cardiol 2006;48(4):215-9.

14. Shavit E, Sherer Y. Hyponatremia induced by amiodarone therapy. Isr Med Assoc J 2007;9(7):564-5.

15. Paydas S, Araz F, Balal M. SIADH induced by amiodarone in a patient with heart failure. Int J Clin Pract 2008;62(2):337.

16. Afshinnia F, Sheth N, Perlman R. Syndrome of inappropriate antidiuretic hormone in association with amiodarone therapy: a case report and review of the literature. Ren Fail 2011;33(4):456-8.

17. Singla S, Strobel AL, Deshmukh AJ, Paydak H. Amiodarone-related hyponatremia: rare but potentially lethal. Am J Ther 2013;20(5):564-5.

18. Pham L, Shuer AJ, Marnejon T. Hyponatremia - a rare but serious complication of amiodarone: a case report and review of the literature. Case Rep Nephrol Urol 2013;3(1):46-50.

19. Dutta P, Parthan G, Aggarwal A, Kumar S, Kakkar N, Bhansali A, et al. Amiodarone induced hyponatremia masquerading as syndrome of inappropriate antidiuretic hormone secretion by anaplastic carcinoma of prostate. Case Rep Urol 2014;2014:136984.

20. Maloberti A, Volpe M, Bombelli M, Dell’oro R, Grassi G. Amiodarone induced SIADH: a case of rare and late onset side effects. Acta Endocrinol (Buc) 2015;11(4):507-11.

21. Nakamura M, Sunagawa O, Kugai T, Kinugawa K. Amiodarone-induced hyponatremia masked by tolvaptan in a patient with an implantable left ventricular assist device. Int Heart J 2017;58(6):1004-7.

22. Hirshberg B, Ben-Yehuda A. The syndrome of inappropriate antidiuretic hormone secretion in the elderly. Am J Med 1997;103(4):270-3.